EBAG9: A Potential Drug Target Or Biomarker for Neurodegenerative Disorders

Target Name: EBAG9

NCBI ID: G9166

EBAG9

EBAG9: A Potential Drug Target Or Biomarker for Neurodegenerative Disorders

EBAG9 (RCAS1_HUMAN), a protein that belongs to the RNA-binding adapter family, plays a crucial role in the regulation of gene expression and has been associated with various diseases, including neurodegenerative disorders. In recent years, researchers have been increasingly interested in studying EBAG9 as a potential drug target or biomarker for a variety of diseases.

The EBAG9 protein is a 9-kDa protein that is expressed in various tissues of the human body, including the brain, heart, and liver. It is composed of a N-terminal transmembrane domain, a C-terminal T-loop, and a variable region that contains multiple domains of variable length. The variable region includes a unique feature called the RNA-binding adapter domain, which is responsible for the protein's ability to interact with RNA molecules.

The RNA-binding adapter domain is a small region of the protein that contains a variety of conserved secondary structure elements, such as a leucine-rich repeat (LRR), a conserved secondary structure, and a hydrogen bonding network. These features make the protein a strong candidate for a drug target or biomarker.

EBAG9 has been shown to play a role in the regulation of gene expression in various organisms, including humans. For example, studies have shown that EBAG9 can interact with specific RNA molecules and regulate their translation efficiency. Additionally, EBAG9 has been shown to be involved. in the regulation of cellular processes such as cell adhesion, migration, and survival.

As a drug target, EBAG9 has the potential to treat a variety of diseases associated with the regulation of gene expression, including neurodegenerative disorders. For example, EBAG9 has been shown to be involved in the development and progression of Alzheimer's disease, a neurodegenerative disorder that is characterized by the accumulation of neurofibrillary tangles and beta-amyloid plaques in the brain.

In addition to its potential as a drug target, EBAG9 has also been shown to be a potential biomarker for the diagnosis and monitoring of neurodegenerative disorders. For example, studies have shown that the levels of EBAG9 in brain tissue are significantly reduced in individuals with Alzheimer's disease compared to age-matched control individuals. Additionally, the levels of EBAG9 have been shown to be decreased in the brains of individuals with other neurodegenerative disorders, such as Parkinson's disease and Huntington's disease.

In conclusion, EBAG9 is a protein that has the potential to be a drug target or biomarker for a variety of neurodegenerative disorders. Its unique RNA-binding adapter domain and its involvement in the regulation of gene expression make it a promising candidate for drug development. Further research is needed to fully understand the role of EBAG9 in the regulation of gene expression and its potential as a drug target or biomarker.

Protein Name: Estrogen Receptor Binding Site Associated Antigen 9

Functions: May participate in suppression of cell proliferation and induces apoptotic cell death through activation of interleukin-1-beta converting enzyme (ICE)-like proteases

The "EBAG9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EBAG9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets